NIH refuses Xtandi march-in request

NIH declined to exercise its march-in rights to allow generic competition for prostate cancer treatment Xtandi enzalutamide from Astellas Pharma Inc.

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE